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Background: To evaluate the predictive and prognostic value of various molecular factors associated with the
Ras/MAPK and PI3K/Akt signaling pathways in HER2-positive locally advanced breast cancer patients treated with
anthracycline-based neoadjuvant chemotherapy (NAC).
Methods: A total of 113 patients were recruited in this retrospective study. Core needle biopsies and excision
samples were assessed through immunohistochemistry for various biomarkers, including IGF-1R, Phospho-p44/42,
Ki67, pAKT, PTEN, p27, and cyclinD1. The changes in these biomarkers after NAC and their predictive and prognostic
values were investigated.
Results: Significant decreases in Ki67, Phospho-p44/42, and pAKT expression were observed after treatment
(30.7% vs. 18.1%, 36.4% vs. 18.9%, and 35.1% vs. 16.4%, respectively). The decreases in Phospho-p44/42, pAKT, and
Ki67 expression were strongly associated with the response to anthracycline treatment (P = 0.027, P = 0.031, and
P = 0.008, respectively). In a multivariate survival analysis, Phospho-p44/42 expression after neoadjuvant chemotherapy
and lymph node status were significant independent prognostic factors of both relapse-free survival and overall survival.
Conclusions: Reductions in Ki-67, Phospho-p44/42, and pAKT expression are related to the clinical response to
anthracycline-based NAC in HER2-positive breast cancer patients. High pAKT expression prior to NAC had a better clinical
response. Phospho-p44/42 expression and lymph node status after NAC could be useful for determining relapse-free
survival and overall survival.
Keywords: Breast cancer, HER2/neu, Neoadjuvant chemotherapy, Overall survival, pAKT, Prognostic factors,
Phospho-p44/42, Relapse-free survivalBackground
Human epidermal growth factor receptor 2 (HER2) is a
tyrosine kinase receptor; up to 25% of women with
early breast cancer are HER2 positive. HER2 is associ-
ated with a more aggressive biological behavior, a
higher likelihood of recurrence after initial treatment,* Correspondence: fdhlyx@gmail.com
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reproduction in any medium, provided the orand poorer prognosis [1]. Three publications have sug-
gested that HER2 positivity is associated with a relative
benefit from anthracycline-containing chemotherapy
compared with non-anthracycline-containing regimens,
which is in agreement with the results of two meta-
analyses [2-6]. Since trastuzumab was approved for use
in HER2-positive breast cancer patients, the prognosis of
breast cancer patients has improved. When used as a
single agent, overall response rates ranging from 15% to
30% have been reported [7].
Neoadjuvant chemotherapy (NAC) has been used in
locally advanced breast cancer to convert previously
unresectable cancer into operable cancer. More recently,Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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breast cancer to reduce tumor volume and allow conser-
vative surgery. The complete pathological response rate
for patients with HER2-positive tumors is nearly 23%,
but the rate has been shown to increase to 40% with
trastuzumab [8]. The additional use of anthracyclines in
combination with trastuzumab is thought to explain the
higher complete pathological response rates observed in
the GeParQuinto trial [9].
HER2 overexpression may lead to increased receptor
homodimerization and heterodimerization, which causes
intrinsic receptor tyrosine kinase activity and induces
phosphorylation of the intracellular domain. The growth
factor receptors utilize several signaling pathways, in-
cluding the Ras/MAPK pathway, which is important for
mitogenic stimulation. They also activate the PI3K/Akt
cascade, which has been shown to be important for cell
survival and inhibiting apoptosis. The PI3K pathway is
downstream of HER2 and is activated to catalyze the
phosphorylation of inositol lipids to produce PIP3 from
PIP2. PIP3 recruits protein kinases and activates the pro-
tein kinase B/AKT pathway. AKT phosphorylation can
inhibit cell cycle arrest. The mitogen-activated protein
kinase (MAPK) signaling pathway is known to be acti-
vated in breast cancer. Extracellular signal-related kinase
(ERK), a member of the MAPK pathway, promotes cell
proliferation, angiogenesis, cell differentiation, and cell
survival.
Insulin-like growth factor receptor-1 (IGFR-1) is a
transmembrane heterotetrameric protein. It is the dom-
inant receptor for the IGF family of molecules, and it
promotes the oncogenic transformation, growth and
survival of cancer cells. IGF-I/II ligand binding induces
intracellular tyrosine kinase activity and triggers a cas-
cade of reactions involving signal transduction pathways,
including the Ras, Raf, MAPK, and PI3K–AKT path-
ways. In breast cancer, IGFR-1 expression and activation
have been linked to disease progression and poor prog-
nosis [10,11].
To improve the efficacy of treatment in HER2-positive
breast cancer patients, it is critical to study the correl-
ation between HER2 signaling pathway activity and the
efficacy of adjuvant treatment. Therefore, we initiated a
retrospective study to collect serial samples of HER2-
positive breast cancer for molecular analyses in patients
undergoing anthracycline-based neoadjuvant chemotherapy.Methods
Ethics statement
The retrospective study was approved by the Ethics
Committee of Shanghai Cancer Center. Written in-
formed consent was obtained from each patient involved
in the study.Patients and clinical samples
From May 2002 to September 2007, 113 patients with
HER2-overexpressing (defined as either 3+ or 2+ with
confirmed c-erbB2 gene amplification by fluorescence in
situ hybridization) stage II to III breast cancer were
retrospectively recruited [12]. Core needle biopsy was
performed for every patient to confirm the diagnosis of
invasive cancer. A complete history, including patient
characteristics, clinical and imaging examinations, and
pathologic assessments of the morphologic and biologic
features of the cancers, was collected. Patients with
metastatic diseases, inflammatory breast cancer or male
breast cancer were not included in this study. All
patients were treated with CEF (cyclophosphamide
600 mg/m2, epirubicin 80 mg/m2 and fluorouracil
500 mg/m2, q3w) or NE (vinorelbine 25 mg/m2 on days
1 and 8 and epirubicin 60 mg/m2 on day 1, q3w). Fol-
lowing completion of neoadjuvant treatment, all patients
underwent breast surgery. For adjuvant chemotherapy,
74.3% of cases had an anthracycline-based regimen, and
10.6% of cases had a paclitaxel regimen; two patients re-
ceived trastuzumab treatment for 1 year. Other standard
therapies, including radiation therapy and endocrine
therapy, were administered at the discretion of the treat-
ing clinician following NCCN guidelines. All patients
were followed-up every 3 months for the first year and
then every 6 months until death.
Assessment of the response to neoadjuvant
chemotherapy
All surgical specimens were submitted for pathological
evaluation. A complete pathological response was de-
fined as no residual invasive carcinoma in the breast or
lymph nodes. The clinical stage and size of the primary
tumor measured by MRI or ultrasonography were re-
corded before treatment. The primary tumor was mea-
sured as the product of its greatest diameter. The
clinical response was evaluated at each cycle of chemo-
therapy and prior to definitive surgery on day 21 of the
last cycle of chemotherapy as the product of the primary
tumor diameters and the axillary clinical status and clas-
sified as a complete response, partial response, stable
disease, or progressive disease according to the solid
tumors criteria (RECIST 1.1).
Immunochemistry
Immunohistochemistry was performed on deparaffinized
sections of all core needle biopsies and surgical tumor
samples. Antibodies for P27, Phospho-p44/42 and pAKT
required antigen retrieval in a pressure cooker. Briefly,
after antigen retrieval, endogenous peroxidases and bio-
tin were blocked with 3% hydrogen peroxide and an
Avidin-Biotin Blocking Kit (Vector, CA), respectively.
This was followed by incubation with the primary
Table 1 Clinical characteristics of HER2-positive breast cancer patients and the univariate analysis of predictive
biomarkers of the response to anthracyclines
Factors Number of
patients (%)













45 years 34 (30%) 10 24 0.975 3 31 0.450
≥45 years 79 (70%) 23 56 11 68
Menopausal status
Postmenopausal 69 (61%) 20 49 0.949 7 62 0.364
Premenopausal 44 (39%) 13 31 7 37
Regimen
CEF 55 (49%) 15 40 0.660 9 46 0.212
NE 58 (51%) 18 40 5 53
Tumor size
≤5 cm 46 (41%) 21 25 0.001 4 42 0.323
>5 cm 67 (59%) 12 55 10 57
Lymph node status
0 43 (38%) - - - - - -
1 to 3 31 (27%) - - - - - -
4 to 9 25 (22%) - - - - - -
≥10 14 (13%) - - - - - -
Pre-estrogen receptor
Negative 78 (69%) 21 57 0.426 10 68 0.835
Positive 35 (31%) 12 23 4 31
Pre-progesterone receptor
Negative 83 (73%) 24 59 0.911 9 74 0.518
Positive 30 (27%) 9 21 5 25
Pre-pMAPK
Negative 34 (30%) 13 21 0.166 8 26 0.855
Positive 79 (70%) 20 59 6 73
Pre-pAKT
Negative 30 (27%) 14 16 0.014 4 26 0.855
Positive 83 (73%) 19 64 10 73
Pre-PTEN
Negative 40 (35%) 13 27 0.568 5 35 0.979
Positive 73 (65%) 20 53 9 64
Pre-P27
Negative 35 (31%) 15 20 0.432 5 40 0.737
Positive 68 (69%) 18 50 9 59
Pre-IGF-1R
Negative 47 (42%) 12 35 0.469 5 42 0.634
Positive 66 (58%) 21 45 9 57
Pre-cyclinD1
Negative 42 (37%) 14 28 0.458 4 38 0.477
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Table 1 Clinical characteristics of HER2-positive breast cancer patients and the univariate analysis of predictive
biomarkers of the response to anthracyclines (Continued)
Positive 71 (63%) 19 52 10 61
Pre-Ki67
Negative 43 (38%) 15 28 0.298 2 41 0.076
Positive 70 (62%) 18 52 12 58
IGF-1R, insulin-like growth factor 1 receptor; pAKT, phosphorylated AkT; pMAPK, phosphorylated mitogen-activated protein kinase.
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appropriate secondary antibody (Dako), labeled strepta-
vidin-horseradish-peroxidase (Dako), DAB chromogen,
and 0.2% osmium tetroxide (Sigma Chemicals, St Louis,
MO), followed by counterstaining with light hema-
toxylin. Appropriate positive controls for each antibody
and negative controls using species-matched immuno-
globulin to replace the primary antibody were run with
each batch. Positive tumor cells were quantified by
evaluating at least 1,000 cells and expressed as percent-
ages. Samples were evaluated by two trained pathologists
(Dr. Zou, Dr. Li) who were blinded to the patient back-
ground and clinical outcome. If the difference between
the two results was more than 10%, a third pathologist
(Dr. Zhou) was consulted.
The cut-off for estrogen receptor (clone 1D5, Dako)
and progesterone receptor (clone PgR 636, Dako) posi-
tivity was 1% of tumor cells with positive nuclear stain-
ing. For Phospho-p44/42 (clone 20G11, Cell Signaling)
and pAKT (clone 736E11, Cell Signaling), the cut-off for
positive expression was 20% of cells with nuclear and
cytoplasmic expression [13]. The cut-off for Ki67 (clone
MIB-1, Dako) positivity was 14% of tumor cells with
positive nuclear staining. The cut-off for other markers
was 10%, including nuclear staining for P27 (clone
SX53G8, Dako) and cyclinD1 (clone EP12, Dako), mem-
branous and cytoplasmic staining for IGF-1R (clone
3027, Cell Signaling), and cytoplasmic and nuclear
staining for PTEN (clone 6H2.1, Dako) [14-16]. The re-
duction between the pre-NAC average percentage andFigure 1 Positive immunohistochemical expression: (A) Ki67, (B) Phospost-NAC average percentage was defined as the reduc-
tion cut-off for Ki67, pAKT, and Phospho-p44/42 (13%,
19%, and 18%, respectively).Statistical analysis
Descriptive statistics were calculated to summarize pa-
tient characteristics, tumor size, and the biomarker
levels in the core needle biopsies and surgical tumor
samples. Biomarker expression levels in pre- and post-
chemotherapy tumor samples were compared using a
paired t test. The initial biomarker levels were compared
between responders and non-responders using the chi-
square test. Fisher’s exact test was performed when ne-
cessary. A simultaneous analysis of the biomarkers that
were significantly predictive of tumor response in the
univariate analysis was performed using a multivariate
logistic regression.
Survival results were last updated in September 2012.
Relapse-free survival was defined as the elapsed time
between the date of first diagnosis and the date of first
relapse. Overall survival was calculated from the date of
diagnosis to the date of death or last follow-up. Patients
without events or death were censored at the last
follow-up. Survival curves were established according to
the Kaplan-Meier method. The log-rank test was used
for univariate comparison of survival endpoints. A Cox
regression was used to assess the relative influence of
prognostic factors on relapse-free survival and overall
survival. All tests were considered significant at a two-pho-p44/42, (C) pAKT, (D) p27, (E) PTEN, (F) IGF-1R, (G) cyclinD1.
Table 2 Univariate analysis of relapse-free survival and overall survival






















0.663 0.9 (0.5 to 1.5) 0.822 1.0 (0.6 to 2.0)
Regimen
CEF vs. NE 0.479 1.2 (0.7 to 2.0) 0.568 1.2 (0.6 to 2.2)
Tumor size
≤5 cm vs. >5 cm 0.784 1.1 (0.6 to 2.0) 0.456 1.3 (0.6 to 2.8)
Lymph node status
Negative
1 to 3 nodes + 0.007 2.7 (1.3 to 5.6) 0.012 4.3 (1.4 to 13.3)
4 to 9 nodes + <0.001 4.6 (2.2 to 9.5) 0.001 7.2 (2.4 to 21.9)







0.252 1.4 (0.8 to 2.3) 0.620 1.2 (0.6 to 2.2) Negative vs.
positive







0.724 0.9 (0.5 to 1.6) 0.334 0.7 (0.3 to 1.5) Negative vs.
positive




0.840 1.1 (0.6 to 1.8) 0.647 0.9 (0.5 to 1.6) Negative vs.
positive




0.174 0.7 (0.4 to 1.2) 0.788 1.1 (0.6 to 2.2) Negative vs.
positive




0.224 0.7 (0.4 to 1.2) 0.104 0.6 (0.3 to 1.1) Negative vs.
positive




0.450 0.8 (0.5 to 1.4) 0.538 0.8 (0.4 to 1.5) Negative vs.
positive




0.929 1.0 (0.6 to 1.6) 0.439 0.8 (0.4 to 1.5) Negative vs.
positive




0.728 1.1 (0.7 to 1.8) 0.874 1.1 (0.6 to 2.0) Negative vs.
positive




0.606 1.2 (0.7 to 2.0) 0.814 1.1 (0.6 to 2.1) Negative vs.
positive
0.602 1.2 (0.7 to 2.1) 0.912 1.0 (0.5 to 2.1)
IGF-1R, insulin-like growth factor 1 receptor; pAKT, phosphorylated AKT; pMAPK, phosphorylated mitogen-activated protein kinase.
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Figure 2 Ki67, Phospho-p44/42 and pAKT expression were significantly decreased after anthracycline treatment. (A) Ki67,
(B) Phospho-p44/42, (C) pAKT.
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Results
Clinical characteristics and responses to NAC
A total of 113 HER2-positive breast cancer patients were
recruited in this retrospective study. The average age of
patients at diagnosis was 49 (range 26 to 78) years;
69 patients were premenopausal at presentation. There
were 67 patients with a baseline tumor size greater than
5 cm. The CEF regimen was given to 55 patients, and
the other patients received the NE regimen. The mean
number of NAC cycles was 3.52 (range 1 to 8), and the
objective response (complete response + partial response)
and non-response rates (progressive disease + stable dis-
ease) were 70.8% and 29.2%, respectively. Eight patients
underwent breast-conserving surgery. The clinical charac-
teristics of these patients are shown in Table 1.
Changes in biomarker expression after NAC
The expressions of various biomarkers (in Figure 1)
before and after NAC were compared in 99 patients
who did not achieve complete pathological response
after NAC. A paired t test analysis found no significant
changes in p27, PTEN, IGF-1R, or cyclinD1 expression
(15.7% vs. 16.5%, 17.0% vs. 18.3%, 49.0% vs. 51.0%, and
18.2% vs. 16.9%, respectively). A significant decrease in
Ki67, Phospho-p44/42, and pAKT expression was ob-
served after treatment (30.7% vs. 18.1%, 36.4% vs. 18.9%,
and 35.1% vs. 16.4%, respectively). We defined positive-
staining tumor cells decreasing by more than the cut-offFigure 3 Correlation between pretreatment and post-treatment mark
the percentage decrease compared to the cut-off value. (A) Ki67, (B) Phospvalue as positive decrease in biomarker expression. The
details are shown in Table 2. Ki67, Phospho-p44/42,
and pAKT expression were all significantly decreased
after anthracycline-based neoadjuvant chemotherapy, as
shown in Figure 2.
Predictors and response to NAC
Biomarkers and clinical characteristics were examined to
investigate their value in predicting the NAC response
(Table 2). Univariate analysis demonstrated that tumor
size and pre-pAKT were predictive factors of the
response to anthracyclines (P = 0.001 and P = 0.014,
respectively). Multivariate analysis demonstrated that
primary tumor size and pAKT expression remained in-
dependent predictive factors of the clinical response to
anthracycline-based NAC (P = 0.012 and P = 0.031, re-
spectively). However, no biomarker could predict a
pathologic complete response. We also found that the
clinical response was coincident with decreased bio-
marker expression, including Ki67, pAKT, and Phospho-
p44/42 (P = 0.001, P = 0.002, and P = 0.007, respectively),
as shown in Figure 3.
Prognostic markers
The median follow-up time was 60 months (ranging
from 14 to 123 months). The overall 5-year relapse-free
survival was 50.4%, and the overall survival was 72.6%. A
univariate analysis (Table 2) demonstrated that the num-
ber of positive lymph nodes and post-Phospho-p44/42
expression were prognostic factors for relapse-free sur-
vival. In the multivariate analysis, the number of positiveers and the pathological response. Values below the line indicate
ho-p44/42, (C) pAKT.
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1.6 to 2.6; P < 0.001) and post-Phospho-p44/42 expres-
sion (hazard ratio, 2.3; 95% confidence interval 1.3 to
4.1; P < 0.001) remained significantly independent prog-
nostic factors. In the univariate analysis (Table 2), lymph
node status (P < 0.001) and post-Phospho-p44/42 expres-
sion (P = 0.019) showed clear associations with overall
survival. In the multivariate analysis, lymph node status
(hazard ratio, 2.3; 95% confidence interval, 1.7 to 3.3;
P < 0.001) and post-Phospho-p44/42 expression (hazard
ratio, 4.3; 95% confidence interval, 2.2 to 8.4; P < 0.001)
were also significant predictors of overall survival. Repre-
sentative survival curves are shown in Figure 4.
Discussion
To our knowledge, this is the largest analysis of
PI3K-Akt and MAPK pathway activation in HER2-
overexpressing breast cancer patients who received an
anthracycline-based neoadjuvant chemotherapy regimen
without trastuzumab.
Owing to its aggressive nature and poor prognosis, a
number of preclinical and clinical studies have focused
on the HER2-positive subtype. The use of anthracyclines
in neoadjuvant treatments for HER2-positive breast can-
cer in addition to trastuzumab is still controversial [17].
HER2 signaling activates pathways (PI3K/Akt and
Ras/MAPK) regulating cell cycle progression and cellFigure 4 Kaplan-Meier curves. Curves for relapse-free survival according
overall survival according to (C) post-Phospho-p44/42 and (D) lymph nodeproliferation. In HER2-overexpressing MBC group,
Gori (et al. found that Phospho-p44/42 and pAKT were
not associated with the clinical outcome, although low
Phospho-p44/42 expression showed a trend for associ-
ation with a longer overall survival [18]. In our study,
the pre-pAKT and pre-Phospho-p44/42 expression rates
were high, and this finding has been confirmed by other
recent studies [19-21]. The results indicate that the
Ras/MAPK and PI3K/Akt pathways are universally
active in locally advanced breast cancer with HER2 over-
expression. However, the PI3K/Akt and Ras/MAPK
pathways have been related to resistance to doxorubicin
and paclitaxel in breast cancer cells [22,23]. The level of
pre-pAKT expression has been shown to have a signifi-
cant correlation with the objective response rates to
anthracycline treatment. It is possible that Akt isoforms
have a distinct impact on the cellular resistance to a
given drug and, in fact, Akt activity does not confer
equal resistance to different chemotherapeutic agents.
For example, the overexpression of constitutively active
Akt isoforms in HeLa cells has been shown to induce
isoform-specific sensitivity to doxorubicin [24]. The role
of pAKT in the neoadjuvant setting is still controversial,
owing to limited investigations, even in large clinical tri-
als. However, decreases in Phospho-p44/42 and pAKT
expression are related to the response to anthracyclines.
Higher levels of active MAPK may have aggressiveto (A) post-Phospho-p44/42 and (B) lymph node status. Curves for
status.
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ated with lymph node metastasis [25]. In the TNBC
subgroup, high ERK protein expression levels and
shorter survival times have been observed [26]. After
anthracycline-based adjuvant treatment, a higher score
was significantly associated with poorer survival follow-
ing relapse compared to a lower expression score among
patients with MAPK overexpression [21].
Furthermore, few studies have presented precise values
for pAKT and Phospho-p44/42 in neoadjuvant chemo-
therapy. In our study, low Phospho-p44/42 expression
after neoadjuvant chemotherapy was a strong prognostic
factor for these patients. Patients with high post-
Phospho-p44/42 expression had a higher recurrence rate
(up to 68%) in the first 5 years, while patients with low
post-Phospho-p44/42 expression had a lower recurrence
rate (45%), and the survival difference between the two
groups was highly significant. It is possible that de-
creased pAKT and Phospho-p44/42 expression promotes
tumor apoptosis and inhibits tumor proliferation, result-
ing in a survival benefit for HER2-positive breast cancer
patients treated with anthracyclines. It is also possible
that topoisomerase IIα expression is regulated by Ras
pathways and tumor proliferation status. The activation
of the Ras/Raf/MAPK pathway has been shown to be
involved in the induction of MRP-1 activity and
topoisomerase IIα downregulation, which are the main
mechanisms of anthracycline resistance [27].
Higher levels of the proliferation marker Ki67 are as-
sociated with poorer survival in breast cancer patients,
but we found no prognostic value for pre-NAC Ki67,
post-NAC Ki67, or the Ki67 fold change. Other studies
have reached controversial conclusions, and it is there-
fore difficult to choose reasonable predictive and prog-
nostic factors among pre-NAC Ki67, post-NAC Ki67,
and Ki67 reduction [14,28-30].
This study has limitations common to all retro-
spective analyses, and it lacked a control group, such
as patients treated with trastuzumab-containing NAC.
However, based on results of big clinical trials, such
as HERA, BCIRG 006, NCCTG N9831, and NSABP
B-31, trastuzumab was approved for adjuvant chemo-
therapy after 2005. In our study, 71% patients were
treated before 2005 when most patients did not re-
ceive trastuzumab in developing countries. Addition-
ally, the number of patients was small. However,
the scientific and clinical community must establish
and evaluate these biomarkers and standardize cut-off
levels. Although a measurement of topoisomerase II-α
amplification was not within the scope of this study,
a possible explanation for our findings may be that
other confounding molecular factors are involved
in the mechanism of the anthracycline response
in HER2-positive patients.Conclusions
In HER2-positive breast cancer patients treated with
anthracyclines, the expression of pAKT, Phospho-p44/
42, and Ki67 decreased significantly after treatment.
Furthermore, patients with high pAKT expression before
NAC had higher objective response rates to anthracy-
clines. The results of our study demonstrate that
Phospho-p44/42 expression after neoadjuvant chemo-
therapy is a strong predictor of outcome. It will be
necessary and valuable to further evaluate potential
therapeutic targets of the PI3K and MEK signaling path-
ways in HER2-positive breast cancer patients.
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